Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Community Participants With COPD or Bronchiectasis and at Risk of Respiratory Viral Infections Including SARS-CoV-2: An Open-label, Multicentre Feasibility Study of an Inhaled Nitric Oxide Generating Solution (RESP301)

NCT04858451 is registered in ClinicalTrials.gov with Thirty Respiratory Limited as lead sponsor.

NCT NCT04858451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04858451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Community Participants With COPD or Bronchiectasis and at Risk of Respiratory Viral Infections Including SARS-CoV-2: An Open-label, Multicentre Feasibility Study of an Inhaled Nitric Oxide Generating Solution (RESP301)
Lead sponsor
Thirty Respiratory Limited
Phase
Phase 2
Overall status
Terminated
Start date
March 1, 2021
Completion date
February 8, 2023
Enrollment
88 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis, copd